Lung Cancer Trials Ask AI to find trials
CompletedPhase 4NCT04180176
Official study title

Prospective Clinicogenomic Program

Study summary

The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. The study will also examine ctDNA status over the course of treatment as a predictor of response to therapy.

Ask AI to explain this study
Start here

Key things to know

Main goalOther

This describes the study’s primary purpose.

What is being studiedBlood Draw

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Small cell lung cancer (SCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 17, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 4

Interventional

Where is it offered?23 U.S. locations

Locations may change over time.

Who runs it?Genentech, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Other
Study type
Interventional
Phase
Phase 4
Sponsor
Genentech, Inc.
Interventions being studied
Other: Blood Draw
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→Small cell lung cancer (SCLC)→
Disease setting
Metastatic or stage IV→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Documented diagnosis of mNSCLC or ES-SCLC
  • Planned initiation of SOC systemic anti-cancer treatment
  • Front-Line Immunotherapy Cohort: Received front-line treatment of an immune blockade therapy including anti-CTLA-4, anti-PD-1, or anti-PD-L1 therapeutic antibody on Protocol GX41563
Reasons someone may not be able to joinExclusion criteria

\- Participant actively receiving investigational medicinal product(s) as part of an interventional trial at the time of signing informed consent

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Alabama OncologyBirmingham, Alabama
  • Clearview Cancer InstituteHuntsville, Alabama
  • Ironwood Cancer & Research CentersChandler, Arizona
  • Yale UniversityNew Haven, Connecticut
  • Florida Cancer Specialists; Department of OncologyFort Myers, Florida
  • Florida Cancer Specialist, North RegionSt. Petersburg, Florida
  • SCRI Florida Cancer Specialists PANTallahassee, Florida
  • Florida Cancer SpecialistsWest Palm Beach, Florida
  • University Cancer & Blood Center, LLC; ResearchAthens, Georgia
  • Piedmont Cancer Institute, PCAtlanta, Georgia
  • Fort Wayne Med Oncology & Hematology IncFort Wayne, Indiana
  • Cancer & Hematology Centers of Western MichiganGrand Rapids, Michigan

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 17, 2024. Always confirm current availability with the study team.

View original record ↗